John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients? PeerVoice Immunology & Infectious Disease Video
-
- Science
Visit https://www.peervoice.com/THE860 to view the entire programme with slides. After completing “John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients?”, participants will be able to: Explain the mechanism of action of anti-IL-23 therapies in ulcerative colitis (UC); Evaluate the latest clinical evidence with anti-IL-23 agents in UC; Discuss evolving treatment goals and definitions of remission in patients with UC; and Define the potential role of anti-IL-23 agents in patients with UC, based on the latest evidence.
Visit https://www.peervoice.com/THE860 to view the entire programme with slides. After completing “John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients?”, participants will be able to: Explain the mechanism of action of anti-IL-23 therapies in ulcerative colitis (UC); Evaluate the latest clinical evidence with anti-IL-23 agents in UC; Discuss evolving treatment goals and definitions of remission in patients with UC; and Define the potential role of anti-IL-23 agents in patients with UC, based on the latest evidence.
17 min